Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center and the University of South Florida, and James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, discuss the biology and diagnostic criteria for myelodysplastic syndrome, as well as advances in the disease presented at the 56th ASH Annual Meeting.

Jan

Today In Oncology

Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

Related Videos

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

Alan F. List, MD, on the CC-5013-MDS-005 Study

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction

AI May Boost Efficacy of Cancer Care but Physicians Remain Critical to Decision Making

Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials